Home > Inhibitors & Agonists > Tyrosine Kinase > Anaplastic Lymphoma Kinase (ALK)
Cat. No. Product name CAS No.
DC7359 ASP3026

ASP3026 is a novel and selective inhibitor for ALK with IC50 of 3.5 nM.

1097917-15-1
DC8138 CEP-28122

CEP-28122 is a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.

1022958-60-6
DC7383 CH5424802(Alectinib)

CH5424802(AF 802; Alectinib) is a potent ALK inhibitor with IC50 of 1.9 nM, sensitive to L1196M mutation.

1256580-46-7
DC8728 CH5424802(Alectinib HCl)

CH5424802(AF 802; Alectinib) is a potent ALK inhibitor with IC50 of 1.9 nM, sensitive to L1196M mutation.

1256589-74-8
DC10547 Ensartinib

Ensartinib is a potent inhibitor of ALK, which is used to treat non-small-cell lung cancer.

1365267-27-1
DC10998 JH-VIII-157-02

JH-VIII-157-02 is a potent, orally active, CNS-permeable, second-generation inhibitor of ALK G1202R mutant with IC50 of 2 nM, also shows high potency against a variety of other frequently observed mutants (G1269A, S1206Y, F1174L and C1156Y).

1639422-97-1
DC8127 KRCA-0008

KRCA-0008 is a potent Ack1 and anaplastic lymphoma kinase (ALK) dual inhibitor (IC50 values are 4 and 12 nM respectively).

1472795-20-2
DC7451 LDN193189 HCl

LDN193189 HCl is a selective BMP signaling inhibitor, inhibits the transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 of 5 nM and 30 nM, respectively, exhibits 200-fold selectivity for BMP versus TGF-β.

1062368-62-0
DC8034 LDN193189 free base

LDN193189 is a selective BMP signaling inhibitor, inhibits the transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 of 5 nM and 30 nM, respectively.

1062368-24-4
DC7303 NVP-TAE684

NVP-TAE684(TAE684) is a highly potent and selective small-molecule ALK inhibitor, which blocked the growth of ALCL-derived and ALK-dependent cell lines with IC50 values between 2 and 10 nM.

761439-42-3
DC7924 PF06463922(Lorlatinib)

PF06463922 is an orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity.

1454846-35-5
DC2047 Crizotinib (PF-2341066)

PF-2341066 (Crizotinib) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nnM, respectivley.

877399-52-5
DC10463 Repotrectinib(TPX-005)

Repotrectinib(TPX-005) is a multi-target macrocycle inhibitor of anaplastic lymphoma kinase (ALK), c-ros proto-oncogene 1 receptor tyrosine kinase (ROS1), and neurotrophic tyrosine kinase receptor (TRK)

1802220-02-5
DC10916 WY-135

WY-135 (WY135) is a novel potent inhibitor of ALK and ROS1 with IC50 of 1.2 and 0.48 nM, respectively.

2163060-83-9
DC28469 TGFβRI-IN-2

TGFβRI-IN-2 (compound 18) is a potent, selective and orally active (Activin-Like Kinase 5) ALK 5 inhibitor with pIC50 and pEC50 values of 7.6 and 6.63, respectively. TGFβRI-IN-2 can produce observed cardiac toxicity in vivo at high dose.

1976038-41-1
DC28690 ALK/ROS1-IN-1

ALK/ROS1-IN-1 (compound 2e) is a potent and selective anti crizotinib-resistant ALK/ROS1 dual inhibitor, with IC50s of 0.174 μM and 0.530 μM for ALK and ROS1 enzyme, respectively.

2365497-07-8
Page 1 / Total 1 FirstPrevNextLastGoto